CETSA (Cellular Thermal Shift Assay)

The patented Cellular Thermal Shift Assay (CETSA®) is a quantitative measure of target engagement and provides a physiologically relevant readout of affinity, adding real value to existing efficacy assays. Using CETSA as a measure for target engagement, will help you make the right decisions faster and improve the quality of your discovery programs.

Who we are

Pelago Bioscience AB was founded in 2013 by the inventors and patent holders of Cellular Thermal Shift Assay (CETSA®) to provide and further develop the method and its applications. The purpose of Pelago is to create positive change in the field of drug discovery. We believe that when implemented on appropriate targets at an early stage, CETSA can significantly reduce pre-clinical drug discovery timelines and reduce the risk of clinical stage failures. Better, safer, sooner drugs, that’s our goal.

What we do

The Cellular Thermal Shift Assay (CETSA®) measures target engagement under actual physiological conditions, without the need to generate modified cell lines. It can be applied against known targets of interest to confirm actual potency both in model systems and patient derived material. Alternatively, it can be applied in a proteome wide approach, such as TPP or PISA that enables unknown targets of a compound to be identified. 


CETSA MS profiled compounds

References to the original CETSA publication

Unique CETSA targets